cancers (pancreaticoduodenectomy).

Although risk factors for cholangiocarcinoma include primary sclerosing cholangitis, congenital biliary malformations, and parasitic liver disease, and hepatolithiasis, none of those was present in the case herein reported. This is the first report the occurrence of a SRC bile duct cancer in a Western patient, and this might be relevant since cholangiocarcinomas in the East possess epidemiology and etiology that are diverse to those bile duct cancers occurring in Western countries. A higher incidence of cholangiocarcinoma in the East has been largely credited to colonization by liver Opiophorhicsiervini and Cronorchis sinusensis, liver flukes that may induce inflammatory changes in the biliary tree and are endemic in Asian countries.

Although one could hypothesize that SCR hilar cholangiocarcinomas would arise from gastric ectopic or metaplastic mucosa, no evidence of gastric mucosa was found in the surgical specimen of the case reported herein. It has also been demonstrated that bile duct epithelium may undergo a sequence hyperplasia-metaplasia-dysplasia-carcinoma similarly to the one of intestinal-type gastric adenocarcinomas. Nevertheless, no evidence for such sequence was found in this case. In fact, biliary SRC carcinomas are poorly-differentiated aggressive tumors that may arise de novo as it is thought to occur in SRC gastric carcinomas. As happened in this case, most cholangiocarcinomas share expression of markers of progenitor cells such as CK7 and CK19. Thus, it is suggested that cholangiocarcinomas are monoclonal tumors that may arise from hepatobiliary pluripotent stem cells.

Another uncommon finding in the case presented here is the association between cholangiocarcinoma and clear cell renal cancer. Although bile duct obstruction could have been attributed to the occurrence of a biliary metastasis from renal cell carcinoma, immunohistochemical analysis confirmed the biliary epithelial origin in this case (positivity for CK19, CK7, CAM 5.2 and AE1+AE3). Renal cell clear carcinomas do not usually stain for all these markers. Although Levy et al. described the occurrence of simultaneous intrahepatic cholangiocarcinoma and a left kidney cancer in a patient on long-term use of methotrexate, there was no previous chronic use of any medications in this case. Thus, the association of a renal cell carcinoma with a SRC Klatskin tumor is likely to be fortuitous in this case.

Cholangiocarcinoma is an aggressive malignant tumor and it is possible that the presence of signet-ring cells could confer additional aggressiveness to this tumor. Further studies will be necessary to confirm or refute this hypothesis.

REFERENCES

1. Gardner HA, Matthews J, Ciano PS: A signet-ring cell carcinoma of the ampulla of Vater. Arch Pathol Lab Med 1990; 114:1071-1072.
2. Hiraki M, Yakushiji H, Hashiguchi K et al: Signet ring cell carcinoma of the lower bile duct with rapid growth: report of a case. Hepatogastroenterology 2007; 54:1922-1924.
3. Karabulut Z, Yildirim Y, Abaci I, Ilgici D, Ozyilkan O: Signet-ring cell carcinoma of the gallbladder: a case report. Adv Ther 2008; 25:220-23.
4. Lee EY, Kim C, Kim MJ et al. Signet ring cell carcinoma of the extrahepatic bile duct. Gut Liver 2010;4:402-6.
5. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M: Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 2003; 16:403–410.
6. Levy BF, Nisar A, Karanjia ND. Cholangiocarcinoma, renal cell carcinoma and parathyroid adenoma found synchronously in a patient on long-term methotrexate. HPB (Oxford) 2006; 8:151-3.
7. Ogata S, Kimura K, Hatusse K et al. Poorly differentiated adenocarcinoma with signet-ring cell carcinoma of the extrahepatic bile duct in a 42-year-old Japanese female: a case report. Acta Med Okayama 2010;64:63-5.
8. Pachar JV, Crooks D, Ermocilla R: Hepatocholangiocarcinoma associated with renal clear cell carcinoma. Rev Med Panama 1987; 12:37-40.
9. Roskams T (2006). Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25:3818–22.
10. Ueda K, Ohori M, Taka J, Kusano M: Metastatic biliary polypoid thrombus from renal cell carcinoma: report of a case. Surg Today 2002; 32:458-61.
morbidity, with patients returning earlier to their activities\textsuperscript{4}. This study aims to report a case diagnosed clinically and genetically, with treatment done through laparoscopic radical gastrectomy.

**CASE REPORT**

Man with 33y was admitted in July 2012 at the General Surgery Service of the Hospital of the Military Police of Paraná, asymptomatic and without comorbidities, but with a family history of gastric cancer in reporting two first-degree relatives with a diagnosis of cancer, one of them younger than 50 years (Figure 1A). After the endoscopy (Figure 1B), was identified ulcerated lesion in the gastric body with positive pathology for adenocarcinoma with histological pattern of signet ring cells (Figure 1C).

**FIGURE 1** – A) Heredogram showing three cases of gastric cancer in three generations of the same family; B) videendoscopy demonstrating gastric ulcer; C) gastric adenocarcinoma (H & E)

Staging showed no metastatic or locally advanced disease. The patient underwent laparoscopic radical gastrectomy with derivation in Roux-en-Y and lymphadenectomy D2. The pathology of the surgical piece showed the presence of poorly differentiated adenocarcinoma, diffuse pattern, with cells in signet ring, free surgical margins and no lymph node compromised histologically in 29 dissected.

After the operation, according to guidelines of the International Gastric Cancer Linkage Consortium, was collected the blood and carried the mutation research of the HRC gene 1. It was analyzed by technique of polymerase chain reaction (PCR) with subsequent bidirectional sequencing of all coding exons and introns-exons junctions CDH1 gene. It was identified as heterozygous deletion of two pairs of bases 1763-1764 in the nucleotide, resulting in frameshift mutation at codon 588 (c.1763-176delTG; pVal588Glu fs * 2) in CDH1 gene.

**DISCUSSION**

This syndrome affects individuals of the same family at young age\textsuperscript{7,10}. It is defined by the presence of germline mutations of CDH1 gene, acquired by autosomal dominant, reaching penetration rates of up to 80% for both genders\textsuperscript{7,10}. The CDH1 gene is located at 16p22.1 gene. It consists of 16 exons encoding a transmembrane protein called E-cadherin. It holds cells together in intra and extracellular domains that communicate with neighboring cells by other proteins called catenines\textsuperscript{4}.

The genetic alterations detected in the CDH1 gene are mutations, frameshift mutations and deletions. Mutations are more related to the occurrence of hereditary diffuse gastric cancer syndrome, the codon 1003, located in exon 7 the most frequent site of changes. In the present study, a frameshift mutation was detected in codon 588, the first of its kind to be described in the literature. The real impact of this mutation on the phenotype is unknown\textsuperscript{6,7}.

Clinical diagnostic criteria are established by the “International Gastric Cancer Linkage Consortium” that defines as the presence of two or more cases of diffuse gastric cancer in first or second degree relatives being one of them diagnosed before age 50, or three or more cases of diffuse gastric cancer diagnosed in first or second degree relatives, regardless of age\textsuperscript{7,10}.

Once established the clinical and genetic diagnosis of the syndrome, it is important to extend the research to the direct family members, and women crawl them for lobular breast carcinoma. Other syndromes may be present at diagnosis, such as colorectal cancer not polyloid, Li-Fraumeni syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome and Cowden\textsuperscript{1}.

Prognosis is dependent on early diagnosis and total gastrectomy indication even in the absence of invasive disease\textsuperscript{9,10}.

Total gastrectomy is the most efficient way to eliminate the risk of developing gastric cancer, including how to limit proximal surgical resection along the distal esophagus and eliminating any risk of residual mucosa tissue on cardia\textsuperscript{9,10}.

Endoscopic surveillance of patients at risk is not the first choice, considering the high penetration rates of the gene, as well as the tendency to multifocality of neoplastic cells and sometimes more initial stages, and the neoplasia below the mucosa. The diffuse histological pattern also carries a worse prognosis due to higher frequency of histologically positive lymph nodes and peritoneal implants\textsuperscript{6,9,10}.

Only in patients who refuse surgical treatment is indicated follow-up with serial endoscopies, added to chromoscopy and immunohistochemistry in biopsies, targeting respectively the largest detection of early gastric cancer and signet ring cells\textsuperscript{4}.

Norton et al.\textsuperscript{4} demonstrated the occurrence of early gastric cancer associated with the syndrome, indicating early radical gastrectomy in six patients. In all surgical specimens had multifocal adenocarcinoma, invasive and histological pattern of signet ring.

Despite the risks of surgery, such as fistulas, infections, dehiscence and anesthetic complications may reach up to 22% of morbidity and mortality of 4%, the benefits of early operation are superior to endoscopic surveillance or the diagnosis of neoplasia in symptomatic patients. Laparoscopy becomes the major route of surgical approach, since the syndrome is prevalent in young patients and its early identification enables the provision of prophylactic operation in the absence of advanced disease, with faster surgical recovery and earlier return to daily activities\textsuperscript{2,10}.
REFERENCES

1. Bertuccio P, Rosato V, Andreana A, Ferraroni M, Decarli A, Edelfonti V, La Vecchia C. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol. 2013; 24(6):1450-8.

2. Bracale U, Pignata G, Lirici MM, et al. Laparoscopic gastrectomies for cancer: The ACOI-IHTSC national guidelines. Minimally Invasive Therapy. 2012; Early Online, 1-7.

3. Brasil. Ministério da Saúde. Instituto Nacional do Câncer. Disponível em: <http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/estomago. Acesso em janeiro de 2014.

4. Chen K, Xu XW, Mou YP, Pan Y, Zhou YC, Zhang RC, Wu D. Systematic Review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World J Surg Oncol. 2013;11:182.

5. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilmard P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerrys VV, Caldas C. International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010 Jul;47(4):346-44.

6. Mastoraki A, Danias N, Arkadopoulos N, Sakorafas G, Vasiou P, Smyriotis V. Prophylactic total gastrectomy for hereditary diffuse gastric cancer. Review of the literature. Surg Oncol 2011; 4:223-6.

7. Matsukuma KE, Mullins FM, Dietz L, Zehnder JL, Ford JM, Chun NM, Schrijver I. Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. Hum Pathol. 2010;41:1200-3.

8. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kuriak AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007 Jun;245(6):873-9.

9. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010 Jul;47(4):346-44.

10. Seevaratnam R, Coburn N, Cardoso R, Dixon M, Bocicatiu A, Helyer L. A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer. 2012;15:153-63.

ABCDDV/1111
ABCD Arq Bras Cir Dig 2015;28(2):148-153

LETTER TO THE EDITOR

Received for publication: 22/04/2014
Accepted for publication: 24/02/2015

doi: http://dx.doi.org/10.1590/ S0102-67202015000200018

RETRORECTAL TUMOR: A CASE REPORT OF A PATIENT WITH “SCHWANNOMA”

Tumor retrorenal: relato de caso de um paciente com “schwanoma”

Henrique Perobelli SCHLEINSTEIN; Paulo Antonio Lemos CURIATI; Marcelo AVEMBERCH; Pedro POPOUTCHI

From the Hospital São Camilo Pompéia (São Camilo Pompéia Hospital), São Paulo, SP, Brazil

Financial source: none
Conflicts of interest: none

Correspondence:
Henrique Perobelli Schleinstein
E-mail: henriqueperobelli@gmail.com

ABCD Arq Bras Cir Dig 2015;28(2):148-153

INTRODUCTION

Injuries that affect the presacral space are rare, and are part of a heterogeneous group of entities of primary concern to colorectal surgeons. These lesions are located in anatomically difficult area to be addressed, hence the need for prior surgical planning, as well as knowledge of the major diseases that affect this region.

The incidence of these lesions varies from 1: 40.000 to 1: 630.000, being more common in females between 40 and 60 years.

CASE REPORT

Man of 94 years showed changes in bowel habits few months ago. Digital rectal examination showed solid pelvic mass with no apparent invasion of the rectal mucosa; it is not possible to predict its upper limit. Computed tomography of the pelvis showed solid-cystic lesion in proximity to the sacrum bone and rectum, with apparent cleavage plane between adjacent structures (Figure 1). He underwent transperitoneal resection of the lesion. Major bleeding occurred during surgery, which was controlled, requiring blood transfusion with four blood cell concentrate units.

Postoperative was without morbidity and discharged on the 7th day after surgery. The pathology confirmed it was schwannoma of low-grade without evidence of malignancy (Figure 2).

FIGURE 1 - Tumor images located in the presacral space

FIGURE 2 - Encapsulated tumor (10 cm in diameter - A) and open aspect (B) showing mucoid material inside

DISCUSSION

Although most retrorectal lesions are congenital, most patients do not have a previous positive family history; the most common clinical presentation is asymptomatic mass found to proctologic examination. The retrorectal masses are palpable on rectal exam by up to 97% of cases.

Due to the angular change caused by the puborectalis muscle mass patients often have changes in bowel habits with a tendency to constipation, feeling of incomplete evacuation or thin stools.

A flexible sigmoidoscopy is useful for viewing the invasion of the rectal mucosa by the tumor and its upper limit, for correct surgical management.

Imaging tests are essential for accurate diagnosis, and the MRI is superior to CT in the characterization of pelvic masses for the presence of bone invasion or neural involvement.

Treatment is mainly surgical. Many of these injuries,